These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38421965)

  • 1. PET/CT and SPECT/CT imaging of 90Y hepatic radioembolization at therapeutic and diagnostic activity levels: Anthropomorphic phantom study.
    Budzyńska A; Kubik A; Kacperski K; Pastusiak P; Kuć M; Piasecki P; Konior M; Gryziński M; Dziuk M; Iller E
    PLoS One; 2024; 19(2):e0271711. PubMed ID: 38421965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioembolization lung shunt estimation based on a
    Kunnen B; van der Velden S; Bastiaannet R; Lam MGEH; Viergever MA; de Jong HWAM
    Med Phys; 2018 Oct; 45(10):4744-4753. PubMed ID: 30179259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility of imaging
    Kunnen B; Dietze MMA; Braat AJAT; Lam MGEH; Viergever MA; de Jong HWAM
    Med Phys; 2020 Mar; 47(3):1105-1114. PubMed ID: 31855282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PET optimization for improved assessment and accurate quantification of 90Y-microsphere biodistribution after radioembolization.
    Martí-Climent JM; Prieto E; Elosúa C; Rodríguez-Fraile M; Domínguez-Prado I; Vigil C; García-Velloso MJ; Arbizu J; Peñuelas I; Richter JA
    Med Phys; 2014 Sep; 41(9):092503. PubMed ID: 25186412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of qualitative and quantitative data of Y-90 imaging in SPECT/CT and PET/CT phantom studies.
    Kubik A; Budzyńska A; Kacperski K; Maciak M; Kuć M; Piasecki P; Wiliński M; Konior M; Dziuk M; Iller E
    PLoS One; 2021; 16(2):e0246848. PubMed ID: 33566845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatopulmonary Shunt Ratio Verification Model for Transarterial Radioembolization.
    Yeyin N; Kesmezacar FF; Tunçman D; Demir Ö; Uslu-Beşli L; Günay O; Demir M
    Curr Radiopharm; 2024; 17(3):276-284. PubMed ID: 38288829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors modulating
    Lopez BP; Mahvash A; Long JP; Lam MGEH; Kappadath SC
    J Appl Clin Med Phys; 2022 Dec; 23(12):e13734. PubMed ID: 35906892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The value of
    Allred JD; Niedbala J; Mikell JK; Owen D; Frey KA; Dewaraja YK
    EJNMMI Res; 2018 Jun; 8(1):50. PubMed ID: 29904808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and Dosimetric Implications of Calculating Lung Shunt Fraction for Hepatic
    Struycken L; Patel M; Kuo P; Hennemeyer C; Woodhead G; McGregor H
    AJR Am J Roentgenol; 2022 Apr; 218(4):728-737. PubMed ID: 34704460
    [No Abstract]   [Full Text] [Related]  

  • 10. Role of yttrium-90 in the management of unresectable hepatocellular carcinoma and hepatic metastases.
    Kousik V; Promila P; Verma R; Gupta A
    Indian J Gastroenterol; 2016 May; 35(3):179-85. PubMed ID: 27185180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative comparison of PET and Bremsstrahlung SPECT for imaging the in vivo yttrium-90 microsphere distribution after liver radioembolization.
    Elschot M; Vermolen BJ; Lam MG; de Keizer B; van den Bosch MA; de Jong HW
    PLoS One; 2013; 8(2):e55742. PubMed ID: 23405207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 99mTc-labelled macroaggregated albumin (MAA) scintigraphy for planning treatment with 90Y microspheres.
    Lambert B; Mertens J; Sturm EJ; Stienaers S; Defreyne L; D'Asseler Y
    Eur J Nucl Med Mol Imaging; 2010 Dec; 37(12):2328-33. PubMed ID: 20683591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 90Y microsphere therapy: does 90Y PET/CT imaging obviate the need for 90Y Bremsstrahlung SPECT/CT imaging?
    Zade AA; Rangarajan V; Purandare NC; Shah SA; Agrawal AR; Kulkarni SS; Shetty N
    Nucl Med Commun; 2013 Nov; 34(11):1090-6. PubMed ID: 23942324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SPECT/CT with 99mTc-MAA in radioembolization with 90Y microspheres in patients with hepatocellular cancer.
    Hamami ME; Poeppel TD; Müller S; Heusner T; Bockisch A; Hilgard P; Antoch G
    J Nucl Med; 2009 May; 50(5):688-92. PubMed ID: 19372479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Partition Model-Based 99mTc-MAA SPECT/CT Predictive Dosimetry Compared with 90Y TOF PET/CT Posttreatment Dosimetry in Radioembolization of Hepatocellular Carcinoma: A Quantitative Agreement Comparison.
    Gnesin S; Canetti L; Adib S; Cherbuin N; Silva Monteiro M; Bize P; Denys A; Prior JO; Baechler S; Boubaker A
    J Nucl Med; 2016 Nov; 57(11):1672-1678. PubMed ID: 27307346
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Debebe SA; Adjouadi M; Gulec SA; Franquiz J; McGoron AJ
    J Appl Clin Med Phys; 2019 Feb; 20(2):30-42. PubMed ID: 30628156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of different CT maps for attenuation correction and segmentation in static
    Lu Z; Chen G; Lin KH; Wu TH; Mok GSP
    Med Phys; 2021 Jul; 48(7):3842-3851. PubMed ID: 34013551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 99mTc-macroaggregated albumin poorly predicts the intrahepatic distribution of 90Y resin microspheres in hepatic radioembolization.
    Wondergem M; Smits ML; Elschot M; de Jong HW; Verkooijen HM; van den Bosch MA; Nijsen JF; Lam MG
    J Nucl Med; 2013 Aug; 54(8):1294-301. PubMed ID: 23749996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fast and accurate quantitative determination of the lung shunt fraction in hepatic radioembolization.
    Bastiaannet R; van der Velden S; Lam MGEH; Viergever MA; de Jong HWAM
    Phys Med Biol; 2019 Nov; 64(23):235002. PubMed ID: 31618717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High quality imaging and dosimetry for yttrium-90 (
    Duan H; Khalaf MH; Ferri V; Baratto L; Srinivas SM; Sze DY; Iagaru A
    Eur J Nucl Med Mol Imaging; 2021 Jul; 48(8):2426-2436. PubMed ID: 33443618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.